胰岛素样生长因子1受体在甲状腺相关眼病中的作用

doi:10.3760/ cma.j.issn.1673-5803.2024.02.011

国际眼科纵览 ›› 2024, Vol. 48 ›› Issue (2): 139-144.doi: 10.3760/ cma.j.issn.1673-5803.2024.02.011

胰岛素样生长因子1受体在甲状腺相关眼病中的作用

吕盼盼¹郝瑞^1,2

¹南开大学附属眼科医院，天津 300020；² 天津市眼科医院天津市眼科研究所天津市眼科学与视觉科学重点实验室，天津 300020

收稿日期:2023-12-09 出版日期:2024-04-22 发布日期:2024-04-22
通讯作者: 郝瑞，Email：haorui0311@126.com
基金资助:
天津市卫生健康科技基金面上项目（TJWJ2021MS041）；天津市医学重点学科（专科）建设项目（TJYXZDXK-016A）；天津市卫生健康行业高层次人才计划（青年医学新锐）（TJSQNYXXR-D2-137）

The role of insulin-like growth factor 1 receptor in thyroid associated ophthalmopathy

Lv Panpan¹, Hao Rui^1,2

¹Nankai University Affiliated Eye Hospital, Tianjin 300020, China; ²Tianjin Eye Hospital, Tianjin Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Tianjin 300020, China

Received:2023-12-09 Online:2024-04-22 Published:2024-04-22
Contact: Hao Rui, Email: haorui0311@126.com
Supported by:
Tianjin Health Science and Technology Fund General Project (TJWJ2021MS041); Tianjin Medical Key Discipline (Specialized) Construction Project (TJYXZDXK-016A); Tianjin Health Industry High level Talent Plan (Young Medical Emerging) (TJSQNYXXR-D2-137)

摘要/Abstract

摘要： 甲状腺相关眼病发病机制尚未完全阐明。胰岛素样生长因子1受体（insulin-like growth factor 1，IGF-1R）的过度表达在甲状腺相关性眼病的发病中具有一定促进作用，其抑制剂替妥木单抗的应用会对甲状腺相关眼病的临床表现及发病过程产生抑制作用。而甲状腺相关眼病患者血清中免疫球蛋白G的升高及β-阻滞蛋白的升高可调节IGF-1R的表达或作用都会对甲状腺相关眼病的临床表现及发病过程产生促进作用。2020年，替妥木单抗成为首个获得美国FDA批准的治疗TAO的药物后，靶向抗IGF-1R治疗和相关临床试验的实施，为研究IGF-1R在TAO发病中的作用与TAO的靶向治疗奠定了基础。（国际眼科纵览，2024, 48：139-144）

关键词: 胰岛素样生长因子受体, 甲状腺相关性眼病

Abstract: The pathogenic mechanisms of thyroid-associated ophthalmopathy (TAO) have not been fully elucidated. Overexpression of insulin-like growth factor 1 receptor (IGF-1R) plays a certain promoting role in the pathogenesis of TAO, and the use of its inhibitor, teprotumumab, can exert an inhibitory effect on the clinical manifestations and progression of TAO. Elevated levels of immunoglobulin G and beta-blocking protein in the serum of TAO patients can regulate the expression or function of IGF-1R, promoting the clinical manifestations and progression of TAO. In 2020, teprotumumab became the first drug approved by the U.S. FDA for the treatment of TAO, and the implementation of targeted anti-IGF-1R therapy and related clinical trials have laid the foundation for studying the role of IGF-1R in the pathogenesis of TAO and targeted therapy for TAO. (Int Rev Ophthalmol, 2024, 48: 139-144)

Key words: insulin-like growth factor-receptor, thyroid-associated ophthalmopathy

吕盼盼郝瑞. 胰岛素样生长因子1受体在甲状腺相关眼病中的作用[J]. 国际眼科纵览, 2024, 48(2): 139-144.

Lv Panpan, Hao Rui. The role of insulin-like growth factor 1 receptor in thyroid associated ophthalmopathy[J]. International Review of Ophthalmology, 2024, 48(2): 139-144.

[1]	林晓璇李金瑛. 甲状腺相关性眼病的眼表损害[J]. 国际眼科纵览, 2023, 47(4): 354-359.
[2]	段春青孙斌. 甲状腺相关性眼病发病机制及动物模型研究[J]. 国际眼科纵览, 2019, 43(6): 421-425.
[3]	王华丽李险峰. 活动期甲状腺相关眼病的诊断与治疗[J]. 国际眼科纵览, 2015, 39(1): 55-60.
[4]	段春青, 孙斌. 眼眶成纤维细胞在甲状腺相关性眼病发病机制中的作用[J]. 国际眼科纵览, 2013, 37(6): 419-423.
[5]	胡依博艾立坤. 甲状腺相关性眼病的病理表现[J]. 国际眼科纵览, 2012, 36(4): 285-288.

胰岛素样生长因子1受体在甲状腺相关眼病中的作用

The role of insulin-like growth factor 1 receptor in thyroid associated ophthalmopathy

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价